Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15418769 | 1.00 | CA14 (0.42) | CA14CA12CA2CA1TSHR | |
| SCHEMBL27041570 | 1.00 | CA14 (0.42) | CA14CA12CA2CA1TSHR | |
| SCHEMBL21685473 | 0.97 | CA12 (0.41) | CA14CA12CA2CA1TSHR | |
| SCHEMBL21685475 | 0.97 | CA12 (0.41) | CA14CA12CA2CA1TSHR | |
| SCHEMBL16083948 | 0.94 | CA14 (0.42) | CA14CA12CA2CA1TSHR | |
| SCHEMBL26130398 | 0.94 | CA14 (0.42) | CA14CA12CA2CA1TSHR | |
| SCHEMBL26130406 | 0.94 | CA14 (0.42) | CA14CA12CA2CA1TSHR | |
| SCHEMBL25637462 | 0.91 | CA14 (0.41) | CA14CA12CA2CA1TSHR | |
| SCHEMBL1197166 | 0.88 | SLC1A1 (0.43) | CA14CA12CA2CA1TSHR | |
| SCHEMBL14125029 | 0.88 | CA14 (0.42) | CA14CA12CA2CA1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4558513-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | Merck Sharp & Dohme LLC (US) | 2025-05-28 | — | — | EP | disclosed |
| CN-118806759-A | Systemic formulations of pyridone derivatives for TG2 related diseases | 福尔克博士药物有限责任公司 | 2024-10-22 | — | — | CN | disclosed |
| WO-2024200819-A1 | PROTEASE INHIBITORS FOR CORONAVIRAL INFECTIONS | PROTINHI B.V. (NL) | 2024-10-03 | — | — | WO | disclosed |
| CN-115867260-B | Systemic formulations of pyridone derivatives for celiac disease | 福尔克博士药物有限责任公司 | 2024-10-01 | — | — | CN | disclosed |
| EP-4408454-A1 | PROTEASE INHIBITORS | Protinhi B.V. (NL) | 2024-08-07 | — | — | EP | disclosed |
| CN-115715187-B | Systemic formulations of pyridone derivatives for TG2 related diseases | 福尔克博士药物有限责任公司 | 2024-07-19 | — | — | CN | disclosed |
| WO-2024020159-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2024-01-25 | — | — | WO | disclosed |
| EP-3965741-B1 | SYSTEMIC FORMULATION OF A PYRIDINONE DERIVATE FOR COELIAC DISEASE | DR FALK PHARMA GMBH (DE) | 2023-06-14 | — | — | EP | disclosed |
| EP-3965742-B1 | SYSTEMIC FORMULATION OF A PYRIDINONE DERIVATE FOR TG2-RELATED DISEASES | DR FALK PHARMA GMBH (DE) | 2023-06-14 | — | — | EP | disclosed |
| EP-3965742-B1 | SYSTEMIC FORMULATION OF A PYRIDINONE DERIVATE FOR TG2-RELATED DISEASES | DR FALK PHARMA GMBH (DE) | 2023-06-14 | — | — | EP | disclosed |
| WO-2014012858-A1 | PYRIDINONE DERIVATIVES AS TISSUE TRANSGLUTAMINASE INHIBITORS | ZEDIRA GMBH (DE) | 2014-01-23 | — | — | WO | disclosed |
| EP-2687511-A1 | Pyridinone derivatives as tissue transglutaminase inhibitors | Zedira GmbH (DE) | 2014-01-22 | — | — | EP | disclosed |
| US-8471063-B2 | Michael systems as transglutaminase inhibitors | ZEDIRA GMBH (DE) | 2013-06-25 | — | — | US | disclosed |
| US-8471063-B2 | Michael systems as transglutaminase inhibitors | ZEDIRA GMBH (DE) | 2013-06-25 | — | — | US | disclosed |
| US-8471063-B2 | Michael systems as transglutaminase inhibitors | ZEDIRA GMBH (DE) | 2013-06-25 | — | — | US | disclosed |
| US-8178490-B2 | Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20110229568-A1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | ZEDIRA GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| US-20110229568-A1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | ZEDIRA GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| US-20110229568-A1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | ZEDIRA GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| WO-2008055488-A1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | ZEDIRA GMBH (DE) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110229568-A1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | TGM2, TGM3, TGM1 | CA14 2294/4885CA12 2136/4885CA2 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.